Sämi Schär

Also affiliated with Texas Instruments (Switzerland), Swiss Group For Clinical Cancer Research

Biochemistry, Genetics and Molecular BiologyMedicineAgricultural and Biological Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)”.

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)

eClinicalMedicine(2023)10.1016/j.eclinm.2023.102221

N/A

0.385DataRank · unranked

12 citations

Martin Fehr, Sämi Schär, Martin Dreyling, Christian Schmidt, Enrico Derenzini +19 more

SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY

Hematological Oncology(2023)10.1002/hon.3163_80

N/A

0DataRank · unranked

3 citations

Maria Cristina Pirosa, Sämi Schär, Marianne Brodtkorb, Björn E. Wahlin, Micaela Hernberg +19 more